Abstract Chronic Haemorrhagic Cystitis (cHC) affects 5–15% of patients after pelvic radiotherapy. Sodium-copper-chlorophyllin, a semi-synthetic chlorophyll derivative, has shown promise in preclinical models. The phase II CLARITY trial evaluated oral chlorophyllin for radiation-induced cHC. This prospective, single-centre, single-arm phase II trial (NCT05348239) enrolled adults with grade 2–4 haematuria persisting ≥ 3 months after pelvic radiotherapy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Rahul
Contact Rahul, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack